News

On March 24, Dr. Maurice McGregor turned 100. Dr. McGregor is affectionately known as the “grandfather of health technology assessment” in Canada. In 2014 CADTH acknowledged his enduring legacy and his immeasurable contributions to Canadian health care by establishing an award in his name. This…
A new project on Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Cancer is now available for feedback from all interested stakeholders. Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Cancer Call for Feedback: 2020-05-22Feedback Due By: 2020…
A new project on Flash Glucose Monitoring System FreeStyle Libre to Monitor Glycemia in Patients With Diabetes is now available for feedback from all interested stakeholders. Flash Glucose Monitoring System FreeStyle Libre to Monitor Glycemia in Patients With Diabetes: Draft Implementation Advice…
Media Advisory Huge response to upcoming CADTH webinar on remdesivir and hydroxychloroquine shows demand among health care decision-makers for evidence on the effectiveness of these therapies. Ottawa, Ontario — More than 1,500 people have registered for a CADTH webinar that will provide an overview…
OTTAWA – The CADTH Board of Directors announced today that Suzanne McGurn has been appointed as the next President and Chief Executive Officer of CADTH, effective July 6, 2020. Ms. McGurn will succeed Dr. Brian O’Rourke, who announced his retirement from CADTH in October 2019 after serving as…
In light of the COVID-19 pandemic, we’ve made some changes to our CADTH Scientific Advice Program activities. During this challenging and uncertain time, we recognize that clinical experts may not be available to participate in our projects. As input from Canadian clinical experts is key to…
CADTH has received the following notice(s) of pending drug submission(s). Brand name TBC Generic name etonogestrel Manufacturer Merck Canada Inc. Indication(s) Prevention of pregnancy Project Number SR0648-000 Call for patient input 2020-05-06 Patient input deadline 2020-06-25 Submit patient input…
CADTH is here to answer your questions about COVID-19. We’ve collected relevant information from CADTH and other respected organizations and published it on our new CADTH/COVID-19 web portal. On this site, you’ll find evidence, tools, and resources covering a range of COVID-19 topics including…
For the latest updates and guidance on COVID-19, please consult the Public Health Agency of Canada. As our country deals with the COVID-19 situation, CADTH has implemented several initiatives to mitigate the risks to our staff and ensure that we continue to support Canada’s health care decision-…
A new project on Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women is now available for feedback from all interested stakeholders. Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women Call for Feedback: 2020-03-05Feedback Due By: 2020-03-…
Today, CADTH has issued final recommendations for: tafamidis (Vyndaqel) Indications: transthyretin-mediated amyloidosisRecommendation: Reimburse with clinical criteria and/or conditions For more information
A new project on Rituximab to Treat Primary Membranous Nephropathy is now available for feedback from all interested stakeholders. Rituximab to Treat Primary Membranous Nephropathy Call for Feedback: 2020-02-13Feedback Due By: 2020-02-28Consultation Document: Proposed Project ScopeProduct Type:…